Payment overview · 2025
General Payments
$357.17
21 reported records · 10 companies
Healthcare provider profile · identity verified
Blake Gordon Phipps, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAWRENCE, KS · NPI 1689084477
Verified facts
What the public records show
CMS Open Payments records show Blake Gordon Phipps, M.D. received $357.17 in general payments during 2025 across 21 reported records.
PFIZER INC. accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.35 | 28.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.78 | 20.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.22 | 12.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.13 | 9.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.46 | 6.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.54 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.46 | 4.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.43 | 4.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $13.98 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.82 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.17 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $102.35 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $102.35 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $102.35 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.78 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.78 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 589 | 163 |
| Lisinopril | Lisinopril | 235 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 54 |
| Metformin Hcl | Metformin Hcl | 189 | 51 |
| Losartan Potassium | Losartan Potassium | 151 | 42 |
| Metformin Hcl Er | Metformin Hcl | 145 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 39 |
| Omeprazole | Omeprazole | 118 | 31 |
| Gabapentin | Gabapentin | 99 | 32 |
| Trazodone Hcl | Trazodone Hcl | 97 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 28 |
| Carvedilol | Carvedilol | 88 | 26 |
| Allopurinol | Allopurinol | 81 | 20 |
| Simvastatin | Simvastatin | 81 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 22 |
| Bupropion Xl | Bupropion Hcl | 79 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 17 |
| Sertraline Hcl | Sertraline Hcl | 68 | 16 |
| Montelukast Sodium | Montelukast Sodium | 63 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 18 |
| Meloxicam | Meloxicam | 56 | 16 |
| Ozempic | Semaglutide | 53 | suppressed |
| Prednisone | Prednisone | 51 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 17 |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Ezetimibe | Ezetimibe | 39 | 11 |
| Pregabalin | Pregabalin | 39 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Spironolactone | Spironolactone | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Furosemide | Furosemide | 31 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.17 · 21 records | PFIZER INC. | ABRYSVO, CAPVAXIVE, COMIRNATY, Fluad, Flucelvax, GARDASIL 9, JARDIANCE, MOUNJARO, OTEZLA, Omnipod, PREVNAR 20, QULIPTA, REPATHA, UBRELVY, VAXNEUVANCE, Veozah, WATCHMAN FLX, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error